先天性肾积水患儿术后罕见并发症:临床病例
- 作者: Kuzovleva G.I.1,2, Luzganova O.S.1, Luzganova V.S.1, Rostovskaya V.V.1, Khvatynets N.А.1,2, Airyan E.K.1,2
-
隶属关系:
- Sechenov First Moscow State Medical University
- Speransky Children’s City Clinical Hospital No. 9
- 期: 卷 15, 编号 1 (2025)
- 页面: 127-135
- 栏目: Case reports
- URL: https://journal-vniispk.ru/2219-4061/article/view/312995
- DOI: https://doi.org/10.17816/psaic1892
- ID: 312995
如何引用文章
全文:
详细
先天性肾积水是一种常见的发育性畸形,通常在产前即可被诊断。由于其高效性(93–98%)和低并发症发生率,腹腔镜肾盂成形术已被公认为治疗肾盂输尿管连接部梗阻的金标准。然而,在肾盂内压骤降、止血不充分或存在凝血障碍的情况下,术后出血仍是一项重要挑战,尤其在使用抗纤溶治疗时尤为明显。本文报道一例右侧先天性肾积水患儿的临床病例。该患儿产前已被诊断为肾积水, 4岁时首次接受泌尿系统X线检查,并被建议手术治疗,但家属当时拒绝。6岁时因反复腹痛和呕吐急诊入院,在病情稳定并缓解疼痛后,通过超声检查、增强CT和排尿性膀胱造影,确诊为“右肾积水,反复右侧肾绞痛”。随后进行了右侧腹腔镜下前血管型肾盂成形术。术后第2天,出现含血引流液和肾盂造口功能障碍。为控制肉眼血尿,使用了具有抗纤溶作用的氨甲环酸治疗,导致肾盂腔被血块填塞。因此进行了再次手术,包括腹腔镜下探查、清除血块并放置额外引流管。术后恢复良好,肾功能和尿液引流均恢复正常,术后过程顺利。该病例强调了术中彻底止血和充分液体治疗在预防并发症中的重要性。对于肾盂成形术后出现肉眼血尿的患者,使用抗纤溶药物应谨慎,因为其存在形成腔内血栓、肾盂填塞乃至肾功能丧失的风险。一旦出现此类并发症,及时的手术干预对器官功能的保留至关重要。
作者简介
Galina I. Kuzovleva
Sechenov First Moscow State Medical University; Speransky Children’s City Clinical Hospital No. 9
编辑信件的主要联系方式.
Email: dr.gala@mail.ru
ORCID iD: 0000-0002-5957-7037
SPIN 代码: 7990-4317
Cand. Sci. (Medicine)
俄罗斯联邦, Moscow; MoscowOlga S. Luzganova
Sechenov First Moscow State Medical University
Email: luzganova.olga@mail.ru
ORCID iD: 0009-0001-6731-3824
俄罗斯联邦, Moscow
Victoria S. Luzganova
Sechenov First Moscow State Medical University
Email: luzganova_v_s@mail.ru
ORCID iD: 0009-0005-4451-856X
SPIN 代码: 7575-8530
俄罗斯联邦, Moscow
Vera V. Rostovskaya
Sechenov First Moscow State Medical University
Email: rostovskaya_vera@mail.ru
ORCID iD: 0000-0002-3718-8911
SPIN 代码: 6989-5041
MD, Dr. Sci. (Medicine)
俄罗斯联邦, MoscowNikolay А. Khvatynets
Sechenov First Moscow State Medical University; Speransky Children’s City Clinical Hospital No. 9
Email: dr.khvatynets@mail.ru
ORCID iD: 0000-0002-9007-6265
SPIN 代码: 9082-7118
MD, Cand. Sci. (Medicine)
俄罗斯联邦, Moscow; MoscowEduard K. Airyan
Sechenov First Moscow State Medical University; Speransky Children’s City Clinical Hospital No. 9
Email: edikayryan@mail.ru
ORCID iD: 0000-0002-8267-0205
SPIN 代码: 9226-2200
MD, Cand. Sci. (Medicine), Associate Professor
俄罗斯联邦, Moscow; Moscow参考
- Vemulakonda V, Yiee J, Wilcox DT. Prenatal hydronephrosis: postnatal evaluation and management. Curr Urol Rep. 2014;15(8):430. doi: 10.1007/s11934-014-0430-5 EDN: QUTOVQ
- Vrublevsky SG, Shnyrov OS, Vrublevskaya EN, et al. Laparoscopic pyeloplasty in children: technique, drainage, complications. Russian Journal of Pediatric Surgery. 2017;21(6):299–302. doi: 10.18821/1560-9510-2017-21-6-299-302 EDN: ZXFZKV
- Metzelder ML, Schier F, Petersen C, et al. Laparoscopic transabdominal pyeloplasty in children is feasible irrespective of age. J Urol. 2006;175(2):688–691. doi: 10.1016/S0022-5347(05)00179-5
- Gubarev VI, Zorkin SN, Shakhnovsky DS, et al. Modern approaches to the treatment of obstructed ureteropelvic junction in children. Russian Journal of Pediatric Surgery. 2017;21(5):262–266. doi: 10.18821/1560-9510-2017-21-5-262-266 EDN: ZIGBVX
- Zakharov AI, Kovarskiy SL, Tekotov AN, et al. Complications of laparoscopic correction of hydronephrosis in children. Russian Journal of Pediatric Surgery, Anesthesia and Intensive Care. 2021;11(3S):51. doi: 10.17816/psaic1095
- Caliskan B, Sinan H, Çağlar U, et al. The effect of the use of tranexamic acid in percutaneous nephrolithotomy on blood loss and surgical visual clarity: a prospective, randomized, controlled and double-blind study. Urolithiasis. 2024;52(1):20. doi: 10.1007/s00240-023-01520-9 EDN: EJRLQP
- Mohammadi Sichani M, Kazemi R, Nouri-Mahdavi K, et al. Re-evaluation of the efficacy of tranexamic acid in reducing blood loss in percutaneous nephrolithotomy: a randomized clinical trial. Minerva Urol Nefrol. 2019;71(1):55–62. doi: 10.23736/S0393-2249.18.03151-X
- Schultz M, van der Lelie H. Microscopic haematuria as a relative contraindication for tranexamic acid. Br J Haematol. 1995;89(3):663–664. doi: 10.1111/j.1365-2141.1995.tb08385.x
- Vujkovac B, Sabovic M. A successful treatment of life-threatening bleeding from polycystic kidneys with antifibrinolytic agent tranexamic acid. Blood Coagul Fibrinolysis. 2006;17(7):589–591. doi: 10.1097/01.mbc.0000245293.41774.c8
- Mehra N, Radhakrishnan V. Tranexamic acid-induced acute renal failure in a pediatric patient with acute myeloid leukemia: a cautionary note. Cancer Research, Statistics and Treatment. 2020;3(3):634–636. doi: 10.4103/CRST.CRST15820
- Maresca G, Royle J, Donaldson JF. Tranexamic acid-induced ureteric clot obstruction in a patient with urothelial cell carcinoma resulting in upper urinary tract perforation. BMJ Case Rep. 2022;15(1):e247334. doi: 10.1136/bcr-2021-247334 EDN: BAUTJW
- Lin P, Fiutowski T, Ansorge C. Using alteplase nephrostomy tube installation for thrombolysis of ureter tract clot obstruction. Urol Case Rep. 2021;36:101561. doi: 10.1016/j.eucr.2021.101561 EDN: KGSMWA
- Kilincaslan H, Leblebisatan G, Tepeler A, et al. Formation of obstructing blood clot in the ureter in a patient with Glanzmann’s thrombasthenia. Blood Coagul Fibrinolysis. 2011;22(8):735–737. doi: 10.1097/MBC.0b013e32834a5c4c
- Ma TK, Chow KM, Kwan BC, et al. Manifestation of tranexamic acid toxicity in chronic kidney disease and kidney transplant patients: a report of four cases and review of literature. Nephrology (Carlton). 2017;22(4):316–321. doi: 10.1111/nep.12762
- Kumar S, Singh S, Parmar KM, et al. Recurrent clot anuria following laparoscopic pyeloplasty in a solitary functioning kidney: managing with double guide wire technique. BMJ Case Rep. 2014;2014:bcr2014206205 . doi: 10.1136/bcr-2014-206205
- Kumar S, Randhawa MS, Ganesamoni R, et al. Tranexamic acid reduces blood loss during percutaneous nephrolithotomy: a prospective randomized controlled study. J Urol. 2013;189(5):1757–1761. doi: 10.1016/j.juro.2012.10.115
- Giusti G, De Lisa A. Blood clots evacuation from the renal pelvis: how to perform it. Int J Urol. 2019;26(5):587–588. doi: 10.1111/iju.13922
- Htaik TT, Santaniello NA, Markmann JF, et al. Treatment of obstructive nephroureteral clot with a rheolytic mechanical thrombectomy device. J Vasc Interv Radiol. 2003;14(7):933–936. doi: 10.1097/01.rvi.0000082826.75926.59
补充文件
